echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The price of Chinese herbal medicines fell sharply by the "Pharmaceutical Speed Reader Society" Green Valley in response to the new specifications of Phase 9.

    The price of Chinese herbal medicines fell sharply by the "Pharmaceutical Speed Reader Society" Green Valley in response to the new specifications of Phase 9.

    • Last Update: 2020-07-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Keytruda-Lenvima combination of first-line treatment of liver cancer rejected; treatment of bald ness Concert innovative JAK oral inhibitors approved by the FDA breakthrough therapy; Zezen Pharmaceuticals Donafini and anti-PD-1 monoantitherapy approved clinical trials; a batch of Chinese herbal drugs prices plummeted dandelion, thyme..;GV-971 Another specification listing application was not approved..Daily fresh medicine to hear medical news, fast-reading society with you to pay attention!In order to further implement the Opinions on the Guarantee of Drug Use for Children (National Health and Drug Administration (2014) No29), the National Health and Care Commission issued a notice on the list of the second Committee of Experts on Child Medication on the 8thAccording to the actual work, the Office of the Committee of Experts is located at the National Children's Medical Center (Beijing Children's Hospital affiliated with the Capital Medical University) and is responsible for day-to-day management; Kiadis Pharma, a, announced today that it has entered into a research and development license agreement with Sanofi to grant Sanofi an exclusive research and development license for Kiadis' previously undisclosed K-NK004 projectK-NK004 is an NK cell therapy that uses genetic engineering to remove CD38 expression(Pharmaceutical MingKang)the official website of the State Drug Administration issued "July 08, 2020 drug notice pending release information", including Shanghai Green Valley Pharmaceutical sodium capsule 450mg specification ganlut (original tentative name: glycosadia di acid, acceptance number: CXHS1800038) related informationGreen Valley Pharmaceuticals replied that the notice related to the content of the company's initiative to withdraw 450mg specificationganut sodium capsule new drug listing application, network transmission "nine phase of a new specification has not been approved" and other content is not consistent with the facts(Green Valley Pharmaceutical Stakes), Mercado and Aishi announced that the U.SFDA has issued a complete response letter (CRL) to the two companies' application for accelerated approval of Keytruda and Lenvima for first-line treatment for patients with non-removable hepatoblastomaThe CRL noted that the early data in the Mersadon and Guardian approval applications did not provide strong evidence that Keytruda-Lenvima had a significant advantage over existing effective treatments(Sina Pharmaceutical news)Concert Pharmaceuticals Corporation announced that the U.S FDA awarded the company's oral Janus kinase (JAK) inhibitor CTP-543 breakthrough therapy for the treatment of patients with moderate to severe bald adults FDA Breakthrough Therapy is expected to accelerate the development and review of this innovative therapy The AstraZeneca and Mercado announced On the 8th that Lynparza (olaparib, Olapari), a PARP inhibitor developed and commercialized by the two sides, has been approved by the European Union for first-line maintenance treatment in patients with metastatic pancreatic cancer with brcA mutation (gBRCAm) who have not progressed after at least 16 weeks of first-line chemotherapy (Sina Pharmaceutical News) Zeyu Pharmaceuticals issued a notice that recently received the Approval of the State Drug Administration issued a "Clinical Trial Notice." This approved to carry out toluene sulfonate Donafini tablets, Trepri sing-injection combined with catheter artery chemotherapy embolism treatment can not be surgically removed liver cell carcinoma ) , Osaikang announced that its independent research and development, with independent intellectual property rights of the new anti-tumor biological drug "ASKB589 injection" approved clinical, intended for CLND18.2 positive local late or metastatic gastric and gastroesophageal combination adenocarcinoma, pancreatic cancer and other malignant solid tumors (Insight database) CDE official website latest data show that the recombinant anti-VEGF humanized monoclonal antibody injection clinical application for East Sunshine drug was accepted, the product is Roche Beva beads mono-anti-injection biosimilar drug, the current market has Qilu Pharmaceuticals, Cinda Biology two domestic enterprises approved Roche's Beval-Beads sing-it-of-global sales have risen slowly in recent years, reaching 7 billion Swiss francs ($7.5 billion) in 2019 (Minnet.com) CDE official website data show that Huahai Pharmaceuticals' Alyssakou collapse tablet 3 types of imitation listing application seisido was accepted According to The Data of Minnet (CDE) the China State Drug Administration's Drug Review Center announced that real creatures in China submitted a new antiviral class 1 drug azvudine (azvudine) listing application, and was accepted on July 9 Azftin tablets are innovative anti-HIV two-target drugs developed by real-world organisms (CDE) Yan Jian and Aishi jointly announced that Yan Jian has completed the U.S FDA application for biological products licensing, seeking approval for the treatment of Alzheimer's disease in the research drug aducanumab This application includes clinical data from Phase 3 clinical trials EMERGE and ENGAGE and Phase 1b clinical trialS PRIME He is also seeking to qualify for priority review Cornerstone Pharmaceuticals has published the results of the Chinese patient study of the key ARROW trial of RET inhibitor Pralsetinib in the global I/II arrow The study data showed that Pralsetinib had superior and long-lasting clinical anti-tumor activity and good tolerance in RET-positive NSCLC patients in China (Amet) Cinda Biopharmaceuticals announced that Cindy Singli sing-it-up (commodity name: Daberschu ®) in conjunction with Sofantini's Phase Ib clinical study to complete the first patient administration in China The study was a phase Ib clinical study conducted in China to evaluate sinditosavic combination of sofanitini for the treatment of subjects of advanced malignancies, and the main purpose of the study was to assess the safety, tolerance and initial anti-tumor activity of Sindili mitud in patients with advanced malignancies with failed standard treatment (AP) Yingshi Bio announced that the company's adhesive plaque kinase (FAK) inhibitor IN10018 single drug and combined chemotherapy second-line and post-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma phase I clinical trial has completed the first patient administration at Tongji University affiliated Oriental Hospital in Shanghai (Americom) according to the query, in the second quarter, a lot of Chinese herbal medicine appeared significantly lower prices, which in contrast to the first quarter of the sharp price increases formed a strong contrast For example, white flowers, prices fell by as much as 76.7%, dandelions, prices fell by as much as 68.8%, and thyme, with prices down as much as 60%.. (Cyber Blue)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.